Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of HCP2001 vs Components in Healthy Volunteers
NCT05155995Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration and Maximum Plasma Concentration. Started Sep 2021; status: completed.
02
Drugs
dapagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05155995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155995.